{"name":"3D Medicines (Beijing) Co., Ltd.","slug":"3d-medicines-beijing-co-ltd","ticker":"","exchange":"","domain":"3dmedicinesbeijing.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"3D185","genericName":"3D185","slug":"3d185","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"3D185","genericName":"3D185","slug":"3d185","phase":"phase_2","mechanism":"3D185 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPUGtfSnRhYWpkb0x5Mm1rS0M3Y3hIY0tMeGNRVlVtb2k5WTRnNkhSXzBKMjk2bEs4MzRpRDh0aWdTRzZLNjAxZjE4WXRnMWhWWkJuYnI4S2FTY0hYYUFwWkRVaGN6dEQwNW84Q1I2cm8zN2lpZnhHcEJUN2pVUTBIWG9uenJqTzBEb3BOZjlwc3NDdzFRNExPd3dnOGpUSDBFQkp5LXJTbExCRE1nZFRfTU9KekxjX1FIa3BHZXQ5dzlyMVp6cmFhVjZqeDdnZw?oc=5","date":"2026-04-02","type":"deal","source":"BioSpace","summary":"Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond - BioSpace","headline":"Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQX3ozaENoNGNLbkhOekpnU2V3OEJtMDBoOE9uQ3R3U0VBQzhlc1UzTTd1V3FiWlJaZFIwVnN0UlVqd2ZMYi1JSjJESG1selJrLWh3Z1p3SG9tNU5kU091RjFPTTVJeEZGMmwtQ1RZUVRGZmIwSkJHaFlaMkh3QkdhZEI1YmY1X0t4R3drSXc4WEU1NFhGNUZkVS1MRXJSbk5EVTRQbVFNdDhhQmgxSU44T2tUOTVQYkpCaldTenA4UFc3MmYwem1rWmhjRUx0M3FPVnVoM2IwaFByOVYtSGd0ZXNZbThfQmV6TElxZUZYRVVUeUE?oc=5","date":"2026-03-31","type":"deal","source":"BioSpace","summary":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform - BioSpace","headline":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platfo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVGFYTVJzS2x0MThmc1ZwOWdxMEtfOGxZOUEwWWhRSU9yRlFpdlQxek1DalRwX0trNkRQYWd5cWZVRUllbUN4YzB1QU1udFRHSDdELVdZM2dsRDd2SXc0M0hXMGZGeV82LUhIRjhIYnRfVXNwNDV5TDVuNlN2QjRqajdnUkpQYmo0X3AybTNnWnZGVWMzczZ4WjBkTWNoTHJYR3EwTVFJelhjdw?oc=5","date":"2026-03-19","type":"pipeline","source":"News-Medical","summary":"ADC efficacy and safety evaluation using advanced organoid models - News-Medical","headline":"ADC efficacy and safety evaluation using advanced organoid models - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPcm85aWxDbkItTmdadFl0ZDdNc05zdEdwUUVhTlE3NS1UY0hnV19DdEtkNlJzcTlMMFNxb1BMRm9HVDNOZW9aNkdha2QyTWxtUExndEoxY05NWERIZzFsYnB2RmFiZlpaYjR1RklmYklZTVFfalJuN1p0X2E0VUhERXRKa1pTbW1uaVE?oc=5","date":"2025-11-27","type":"pipeline","source":"ThinkChina","summary":"Where China stands in the nuclear medicine gold rush - ThinkChina","headline":"Where China stands in the nuclear medicine gold rush","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-05","type":"trial","source":"Moneycontrol.com","summary":"Glenmark shares rally over 2.5 percent on muti-nation Phase 3 trial for cancer drug Envafolimab - Moneycontrol.com","headline":"Glenmark shares rally over 2.5 percent on muti-nation Phase 3 trial for cancer drug Envafolimab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPX2p4VEc1Z3NYNFZhVU9EWE1nd2hESFFMR08zMGJhanp4eFlVLXE0bGluVmV6MmVIMkVwYXZlYnhnbFo3dlRiODEyRnJxcjMwNlpCeEotMWZrTDJCQWZvb3RGamY2RlZWSFQ5UUdhbjJ3X09YYmVOdnBmV0xZa2pxczB6UnhHZG5oMW1KcnAzdHg4bEhLeDh1TlZ0SENlQkxqLU1HM0RUdW0yNENfenNqV1lPbGlCdkVXTzVHUVdxck03Mkh4QlZoWFZLTHJ4ME1jbzhQYjM5c2JxWlBCY1lUbUlvM2h4ZGVTZUE?oc=5","date":"2025-07-10","type":"pipeline","source":"BioSpace","summary":"Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - BioSpace","headline":"Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE81dnJyNUpieWprYzRlTjhtSl9yRUhZZXRXaVJrTzBKYTE1dS15Q0lLSnZpT0dTZFpBaUtjMTRkVzZ5b3dUOWZ4MDdEOV9yTU1WVDlDVHBR?oc=5","date":"2025-07-09","type":"pipeline","source":"Yahoo! Finance Canada","summary":"TransThera Sciences (Nanjing), Inc. (2617.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"TransThera Sciences (Nanjing), Inc. (2617.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFAxTnpxc2dISTNnVXpBaTd0dWhHT1AzeTNfWUhMQmZuY0toMHB1eGM4Y0RCckxnaXpnMTE3My1UWFFNdENZT3YzWXNOaWFUam9uSkR2dW1qMlBpQ1BoV3pr?oc=5","date":"2025-03-27","type":"trial","source":"Nature","summary":"AlphaFold is running out of data — so drug firms are building their own version - Nature","headline":"AlphaFold is running out of data — so drug firms are building their own version","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV0hzT3N1dk10djRZX3Y1TGlNVWhFUGlQWGxvS2VqaHJQekNwQ3NmMnJUUTRXaUJrZjg2ejl4UUJ1aUFKOGhQRm9wOFpyT2hYNUVXdmlfN2NzLWxqb2k5bnM0d2NWX3N0QlRRWGFBRkdfOUI5V2Y2SGdnMlR4bHZ4SE50amdTQ3hXVXVFUHIyODcwNWcwa1E4Z29wbktCaTI4QTVFSFFKekU?oc=5","date":"2024-07-02","type":"trial","source":"BioWorld News","summary":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop - BioWorld News","headline":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNd2ZiWkdHMXRkUUZuWWtCbUx6OFRIRHFGOHZaWTF5ZjAteExrVF9lSFQ0dnFkX0czWXg2Nk4wVGhud0lCd25tWEtNZm5HSkllam42VmdReFBrZjdhNlNFQ3hhX3J4ZS15ZjRrcHcxR1hTNnYwcWcxeEhSZFZudzFnaVBNS25nOG55RUhfM3ZERWozOGxFMkZTT1c4bVkwdlZMb3pLNEZXQmM3SXRhQVdCQ011VGJWNWpRQkhmMXZQRVZpR2NIVFFSNmE2Y1cwel9IXzBxS3JaNnV0YjFLZmpHdmVpaFd6dGtBUnBMYm5NcERINzZyVDgzLXdvT1lhVWxzdW53VkxXYlpTR2cxNk1oYWI5TThtT0FTYy04c2syUEhLcDBtUTB6V3RCRm9JdG9saVNWT1RZN0xNdzVxR28yUWRmWXpkWXF2?oc=5","date":"2024-01-25","type":"deal","source":"PR Newswire","summary":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World - PR Newswire","headline":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (En","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPQXpJSzZFVk54UVIyNi1VZjhFNDRTR28yaWRDdHBHSGdEYkJDcGR1Q3JXcmNZSnM3NnVtVEtNSWFaN3d4UmlXQ2pjb3d6cmtidnBGTHVadEpUa0txWlhhYzJzZ3FjaFQzNUl1MEp1MTh2ZEpTZHJoWTdEdDU1TDE4MUlBR2FpcFlaUDhvS05MY2RFRXdRa3hITU5xNTA0RWpxejl4dUV0dTIyYllzaDlDTlRfVG9jRnU5cDA3S3FNaUYxakozUGYwZ1dYTDBHTkk1elp5dTNLRmQ4XzhSek1CdHpUSkxoVmxWektHdFQ4aElaM1Q4XzNSVmkxbnBVc2RtOFVQbEdZY1PSAY4CQVVfeXFMTnVQN2ZxRGppWmdoNlV4OVdoR3hpVHZKVnBHTnFKLW5haldJUGx1S3hDcVg5amNzendYU0RRRkFDd29xRHY2WGNVR1hFZnZIMURhbnYwVEZKckkwRWdGbmgzUDlEakZINWIzcWhaaTU0cjVSSlBaYzdDQ0VWdlJPZkE1ZDR3cUhJZFFMMkZ1ODMwRHhkby14eFNVV21taWwxdktSQ3ZPT3RKU3hUTW94M1VybXFnVDRGaXgwX2xDSjVKdjFYNlFDeGZ3c2tYMDhKYTlXcUp5UktDM2RiQmhySFE0dzZJMUp4Tk1ldS1ZSVc3ekxwS1FyREpmX0hVaENHb1lLZExMSEMzU040QWhR?oc=5","date":"2024-01-25","type":"pipeline","source":"The Economic Times","summary":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug - The Economic Times","headline":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}